ECSP10010414A - Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismos - Google Patents
Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismosInfo
- Publication number
- ECSP10010414A ECSP10010414A EC2010010414A ECSP10010414A ECSP10010414A EC SP10010414 A ECSP10010414 A EC SP10010414A EC 2010010414 A EC2010010414 A EC 2010010414A EC SP10010414 A ECSP10010414 A EC SP10010414A EC SP10010414 A ECSP10010414 A EC SP10010414A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical compositions
- same
- compositions containing
- antagonist activity
- tricyclic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
RESUMENSe proporciona un compuesto de la fórmula (I'): en donde X es un nitrógeno o CRx, Rx es un hidrógeno, etc., R1 es un grupo de hidrocarburo opcionalmente substituido etc., R2 es un grupo de hidrocarburo opcionalmente substituido, etc., el anillo A es un anillo heterocíclico de 5- a -8-miembros etc., y cada uno de Y1,. Y2 e Y3 es un carbono opcionalmente substituido o un nitrógeno, etc.; o una sal del mismo o un profármaco del mismo, que tiene actividad antagonista del receptor CRF y proporciona también el uso del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US655408P | 2008-01-22 | 2008-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010414A true ECSP10010414A (es) | 2010-09-30 |
Family
ID=40637104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010414A ECSP10010414A (es) | 2008-01-22 | 2010-08-20 | Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8785460B2 (es) |
| EP (1) | EP2240485B1 (es) |
| JP (1) | JP5431341B2 (es) |
| KR (1) | KR20100130596A (es) |
| CN (1) | CN101981031A (es) |
| AR (1) | AR070218A1 (es) |
| AU (1) | AU2009206936A1 (es) |
| BR (1) | BRPI0907230A2 (es) |
| CA (1) | CA2712347A1 (es) |
| CL (1) | CL2009000116A1 (es) |
| CO (1) | CO6230982A2 (es) |
| CR (1) | CR11636A (es) |
| DO (1) | DOP2010000226A (es) |
| EA (1) | EA201070876A1 (es) |
| EC (1) | ECSP10010414A (es) |
| GE (1) | GEP20125637B (es) |
| IL (1) | IL207074A0 (es) |
| MA (1) | MA32438B1 (es) |
| MX (1) | MX2010008039A (es) |
| NZ (1) | NZ587215A (es) |
| PE (1) | PE20091439A1 (es) |
| SG (1) | SG189803A1 (es) |
| TW (1) | TW200936591A (es) |
| UY (1) | UY31604A1 (es) |
| WO (1) | WO2009093747A1 (es) |
| ZA (1) | ZA201005340B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| WO2010093425A1 (en) | 2009-02-11 | 2010-08-19 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| WO2011031818A2 (en) * | 2009-09-11 | 2011-03-17 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| MY166866A (en) | 2011-08-18 | 2018-07-24 | Nippon Shinyaku Co Ltd | Heterocyclic derivative and pharmaceutical drug |
| EP2825541B1 (en) | 2012-03-16 | 2016-06-22 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
| JP6114815B2 (ja) | 2012-03-16 | 2017-04-12 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | 肝臓ｘレセプターモジュレーター |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| CN103435618B (zh) * | 2013-08-22 | 2016-03-23 | 中国药科大学 | 一种合成稠杂环化合物的方法 |
| KR20170005868A (ko) * | 2014-05-23 | 2017-01-16 | 액티브 바이오테크 에이비 | S100-저해제로서 유용한 새로운 화합물 |
| CN105859630B (zh) * | 2015-01-22 | 2019-01-18 | 北京大学 | 一种咪唑酮衍生物的合成方法及应用 |
| EP3356369B1 (en) | 2015-10-01 | 2022-05-04 | Idemitsu Kosan Co., Ltd | Benzimidazolo[1,2-a]benzimidazole carrying triazine groups for organic light emitting diodes |
| EP3150604B1 (en) | 2015-10-01 | 2021-07-14 | Idemitsu Kosan Co., Ltd. | Benzimidazolo[1,2-a]benzimidazole carrying benzimidazolo[1,2-a]benzimidazolylyl groups, carbazolyl groups, benzofurane groups or benzothiophene groups for organic light emitting diodes |
| WO2018220513A1 (en) * | 2017-05-31 | 2018-12-06 | Alembic Pharmaceuticals Limited | An improved process for preparation of obeticholic acid |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS516993A (en) | 1974-07-05 | 1976-01-20 | Dainippon Pharmaceutical Co | Adeninjudotaino seiho |
| HUP0303653A3 (en) | 2000-12-28 | 2006-05-29 | Ono Pharmaceutical Co | Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| EP1637521B1 (en) | 2003-06-23 | 2013-06-19 | Ono Pharmaceutical Co., Ltd. | Novel tricyclic heterocycle compound |
| US7897607B2 (en) | 2004-04-07 | 2011-03-01 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| WO2008051533A2 (en) | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
| EP2125753A1 (en) | 2006-12-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds having crf antagonistic activity |
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| FR2926554B1 (fr) * | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| CL2009000119A1 (es) | 2008-01-22 | 2010-03-05 | Boehringer Ingelheim Int | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. |
-
2009
- 2009-01-21 US US12/357,158 patent/US8785460B2/en not_active Expired - Fee Related
- 2009-01-21 US US12/863,851 patent/US8901141B2/en not_active Expired - Fee Related
- 2009-01-21 CL CL2009000116A patent/CL2009000116A1/es unknown
- 2009-01-21 JP JP2010528624A patent/JP5431341B2/ja not_active Expired - Fee Related
- 2009-01-21 TW TW098102200A patent/TW200936591A/zh unknown
- 2009-01-21 CN CN2009801105455A patent/CN101981031A/zh active Pending
- 2009-01-21 SG SG2013029723A patent/SG189803A1/en unknown
- 2009-01-21 KR KR1020107018307A patent/KR20100130596A/ko not_active Withdrawn
- 2009-01-21 GE GEAP200911925A patent/GEP20125637B/en unknown
- 2009-01-21 UY UY031604A patent/UY31604A1/es not_active Application Discontinuation
- 2009-01-21 AU AU2009206936A patent/AU2009206936A1/en not_active Abandoned
- 2009-01-21 CA CA2712347A patent/CA2712347A1/en not_active Abandoned
- 2009-01-21 MX MX2010008039A patent/MX2010008039A/es not_active Application Discontinuation
- 2009-01-21 WO PCT/JP2009/051299 patent/WO2009093747A1/en not_active Ceased
- 2009-01-21 EA EA201070876A patent/EA201070876A1/ru unknown
- 2009-01-21 NZ NZ587215A patent/NZ587215A/xx not_active IP Right Cessation
- 2009-01-21 BR BRPI0907230A patent/BRPI0907230A2/pt not_active IP Right Cessation
- 2009-01-21 PE PE2009000069A patent/PE20091439A1/es not_active Application Discontinuation
- 2009-01-21 AR ARP090100180A patent/AR070218A1/es not_active Application Discontinuation
- 2009-01-21 EP EP09704168.5A patent/EP2240485B1/en active Active
-
2010
- 2010-07-18 IL IL207074A patent/IL207074A0/en unknown
- 2010-07-21 DO DO2010000226A patent/DOP2010000226A/es unknown
- 2010-07-27 ZA ZA2010/05340A patent/ZA201005340B/en unknown
- 2010-08-13 MA MA33084A patent/MA32438B1/fr unknown
- 2010-08-18 CR CR11636A patent/CR11636A/es not_active Application Discontinuation
- 2010-08-20 CO CO10102942A patent/CO6230982A2/es active IP Right Grant
- 2010-08-20 EC EC2010010414A patent/ECSP10010414A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA32438B1 (fr) | 2011-07-03 |
| BRPI0907230A2 (pt) | 2019-09-24 |
| CR11636A (es) | 2010-11-04 |
| EP2240485A1 (en) | 2010-10-20 |
| PE20091439A1 (es) | 2009-10-19 |
| SG189803A1 (en) | 2013-05-31 |
| TW200936591A (en) | 2009-09-01 |
| KR20100130596A (ko) | 2010-12-13 |
| AR070218A1 (es) | 2010-03-25 |
| US20100298287A1 (en) | 2010-11-25 |
| WO2009093747A1 (en) | 2009-07-30 |
| US8785460B2 (en) | 2014-07-22 |
| UY31604A1 (es) | 2009-08-31 |
| US8901141B2 (en) | 2014-12-02 |
| JP2011509923A (ja) | 2011-03-31 |
| EA201070876A1 (ru) | 2011-04-29 |
| NZ587215A (en) | 2012-08-31 |
| CL2009000116A1 (es) | 2010-08-27 |
| DOP2010000226A (es) | 2010-10-15 |
| JP5431341B2 (ja) | 2014-03-05 |
| US20090186879A1 (en) | 2009-07-23 |
| AU2009206936A1 (en) | 2009-07-30 |
| GEP20125637B (en) | 2012-09-10 |
| IL207074A0 (en) | 2010-12-30 |
| MX2010008039A (es) | 2010-08-10 |
| CN101981031A (zh) | 2011-02-23 |
| CA2712347A1 (en) | 2009-07-30 |
| EP2240485B1 (en) | 2014-10-15 |
| ZA201005340B (en) | 2011-10-26 |
| CO6230982A2 (es) | 2010-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010414A (es) | Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismos | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| HN2010001059A (es) | Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes. | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| MX2010008375A (es) | Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3). | |
| CL2013002821A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina; composicion farmaceutica que los comprende; y su uso como antagonista de los receptores tropomiosina (trk) para el tratamiento del dolor. | |
| BRPI0813218A2 (pt) | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. | |
| AR068813A1 (es) | Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata | |
| UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
| ECSP13012771A (es) | Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos | |
| DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| NI200900042A (es) | Nuevo derivados de dismetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
| PE20150598A1 (es) | Derivados de n-prop-2-inil carboxamida y su uso como antagonistas del receptor transitorio potencial de la subfamilia a, miembro 1 | |
| ECSP088265A (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| WO2009057784A1 (ja) | 複素環化合物 | |
| MY150062A (en) | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| MX390264B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. |